Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

作者：Derks Sarah; Liao Xiaoyun; Chiaravalli Anna M; Xu Xinsen; Camargo M Constanza; Solcia Enrico; Sessa Fausto; Fleitas Tania; Freeman Gordon J; Rodig Scott J; Rabkin Charles S; Bass Adam J^*

来源：Oncotarget, 2016, 7(22): 32925-32932.

DOI：10.18632/oncotarget.9076

• EBV-infected gastric cancers
• MSI gastric cancer
• PD-L1
• PD-1 inhibitors

Gastric cancer (GC) is a deadly disease with limited treatment options. Recent studies with PD-1 inhibition have shown promising results in GC, but key questions remain regarding which GC subclass may respond best. In other cancers, expression of the PD-1 ligand PD-L1 has been shown to identify cancers with greater likelihood of response to PD-1 blockade. We here show with immunohistochemistry that Epstein-Barr Virus (EBV) + GCs (n = 32) have robust PD-L1 expression not seen in other GCs. In EBV+ GC, we observed PD-L1 staining in tumor cells in 50% (16/32) and immune cells in 94% (30/32) of cases. Among EBV-negative GCs, PD-L1 expression within tumors cells was observed only in cases with microsatellite instability (MSI), although 35% of EBV-/MSS GCs possessed PD-L1 expression of inflammatory cells. Moreover, distinct classes of GC showed different patterns of PD-L1+ immune cell infiltrations. In both EBV+ and MSI tumors, PD-L1+ inflammatory cells were observed to infiltrate the tumor. By contrast, such cells remained at the tumor border of EBV-/MSS GCs. Consistent with these findings, we utilized gene expression profiling of GCs from The Cancer Genome Atlas study to demonstrate that an interferon-gamma driven gene signature, an additional proposed marker of sensitivity to PD-1 therapy, were enriched in EBV+ and MSI GC. These data suggest that patients with EBV+ and MSI GC may have greater likelihood of response to PD-1 blockade and that EBV and MSI status should be evaluated as variables in clinical trials of these emerging inhibitors.

• 出版日期2016-5-31